Reduction of Diabetic Macular Edema in the Untreated Fellow Eye Following Intravitreal Injection of Aflibercept

Copyright 2016, SLACK Incorporated.

Bibliographische Detailangaben
Veröffentlicht in:Ophthalmic surgery, lasers & imaging retina. - 2013. - 47(2016), 5 vom: 01. Mai, Seite 474-6
1. Verfasser: Calvo, Charles M (VerfasserIn)
Weitere Verfasser: Sridhar, Jayanth, Shahlaee, Abtin, Ho, Allen C
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2016
Zugriff auf das übergeordnete Werk:Ophthalmic surgery, lasers & imaging retina
Schlagworte:Case Reports Journal Article Recombinant Fusion Proteins aflibercept 15C2VL427D Receptors, Vascular Endothelial Growth Factor EC 2.7.10.1
LEADER 01000naa a22002652 4500
001 NLM260386154
003 DE-627
005 20231224193303.0
007 cr uuu---uuuuu
008 231224s2016 xx |||||o 00| ||eng c
024 7 |a 10.3928/23258160-20160419-12  |2 doi 
028 5 2 |a pubmed24n0867.xml 
035 |a (DE-627)NLM260386154 
035 |a (NLM)27183553 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Calvo, Charles M  |e verfasserin  |4 aut 
245 1 0 |a Reduction of Diabetic Macular Edema in the Untreated Fellow Eye Following Intravitreal Injection of Aflibercept 
264 1 |c 2016 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 26.06.2017 
500 |a Date Revised 01.12.2017 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Copyright 2016, SLACK Incorporated. 
520 |a A 59-year-old patient with bilateral worsening diabetic macular edema received intravitreal injection of aflibercept (Eylea; Regeneron, Tarrytown, NY) to the left eye only. On 1-month follow-up, there was noted bilateral improvement of visual acuity and diabetic macular edema on spectral-domain optical coherence tomography imaging, reflecting bilateral effect of unilateral treatment with aflibercept. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:474-476.] 
650 4 |a Case Reports 
650 4 |a Journal Article 
650 7 |a Recombinant Fusion Proteins  |2 NLM 
650 7 |a aflibercept  |2 NLM 
650 7 |a 15C2VL427D  |2 NLM 
650 7 |a Receptors, Vascular Endothelial Growth Factor  |2 NLM 
650 7 |a EC 2.7.10.1  |2 NLM 
700 1 |a Sridhar, Jayanth  |e verfasserin  |4 aut 
700 1 |a Shahlaee, Abtin  |e verfasserin  |4 aut 
700 1 |a Ho, Allen C  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Ophthalmic surgery, lasers & imaging retina  |d 2013  |g 47(2016), 5 vom: 01. Mai, Seite 474-6  |w (DE-627)NLM224956647  |x 2325-8179  |7 nnns 
773 1 8 |g volume:47  |g year:2016  |g number:5  |g day:01  |g month:05  |g pages:474-6 
856 4 0 |u http://dx.doi.org/10.3928/23258160-20160419-12  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_40 
912 |a GBV_ILN_63 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_90 
912 |a GBV_ILN_91 
912 |a GBV_ILN_130 
912 |a GBV_ILN_135 
912 |a GBV_ILN_136 
912 |a GBV_ILN_151 
912 |a GBV_ILN_181 
912 |a GBV_ILN_203 
912 |a GBV_ILN_217 
912 |a GBV_ILN_235 
912 |a GBV_ILN_289 
912 |a GBV_ILN_294 
912 |a GBV_ILN_297 
912 |a GBV_ILN_350 
912 |a GBV_ILN_352 
912 |a GBV_ILN_674 
912 |a GBV_ILN_676 
912 |a GBV_ILN_688 
912 |a GBV_ILN_698 
912 |a GBV_ILN_721 
912 |a GBV_ILN_737 
912 |a GBV_ILN_791 
912 |a GBV_ILN_812 
951 |a AR 
952 |d 47  |j 2016  |e 5  |b 01  |c 05  |h 474-6